Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CPI-444
Ciforadenant · 3 trials · 4 indications
Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.5
Area under the plasma concentration-time curve (AUC) from time zero to infinity
AUC from time zero to the last quantifiable concentration
Percentage of AUC0-∞ that was due to extrapolation from the last quantifiable concentration to infinity
| Arm | Type | Description |
|---|---|---|
| Ciforadenant in combination with daratumumab | EXPERIMENTAL | Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg. |
| Sequence ABC | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed). |
| Sequence BCA | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted). |
| Sequence CAB | ACTIVE_COMPARATOR | 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted). |
| Cohort 1 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 2 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 3 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 4 | EXPERIMENTAL | Ciforadenant + atezolizumab |
| Cohort 5 - Closed | EXPERIMENTAL | Ciforadenant |
| Name | Type | Description |
|---|---|---|
| Ciforadenant | DRUG | 100 mg orally twice daily for 28-day cycles |
| daratumumab | DRUG | 16 mg/kg administered intravenously as follows based on 28-day cycles: * Cycles 1 - 2: Days 1, 8, 15, and 22 * Cycles 3 - 6: Days 1 and 15 * Cycles 7 - 24: Day 1 |
| CPI-444 Capsules | DRUG | 100mg Capsule |
| CPI-444 Tablets | DRUG | 100mg Tablets |
| Ciforadenant + atezolizumab | DRUG | Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously. |
Inclusion Criteria: * Relapsed or refractory myeloma. * Must have been exposed to at least 2 cycles of an IMiD containing regimen and PI containing regimen and must be refractory to at least one of the two. * Must have completed and tolerated 2 cycles of daratumumab or other anti-CD38 targeting ant...
Top 20 of 25 competitors
Ciforadenant is an investigational small molecule cancer therapy developed by Corvus Pharmaceuticals, Inc. (ticker CRVS). It has been studied in clinical trials for multiple myeloma and renal cell cancer, as well as metastatic castration resistant prostate cancer. It is not an approved medicine and remains in clinical development.
Ciforadenant targets ADORA2A, the adenosine A2A receptor, and acts as an antagonist. By blocking this receptor, the drug is designed to interfere with adenosine-mediated signaling in the tumor microenvironment. This target class places ciforadenant among small molecule adenosine pathway inhibitors being studied in oncology.
Ciforadenant has been studied in multiple myeloma and renal cell cancer. One trial evaluated it with daratumumab in relapsed or refractory multiple myeloma, and a separate Phase 1/1b study enrolled patients with renal cell cancer and metastatic castration resistant prostate cancer. It is investigational and not approved for any use.
Ciforadenant is developed by Corvus Pharmaceuticals, Inc., which trades under the ticker CRVS. The company is the sponsor of the clinical program evaluating the drug in hematologic and solid tumor cancers.
Ciforadenant is in Phase 1 development. Its trials are listed as Phase 1 or Phase 1/1b and have been completed, with no active trials currently recorded. The drug is investigational and has not been approved by the FDA for any indication.
Ciforadenant has been evaluated in two completed studies. NCT04280328 tested ciforadenant with daratumumab in relapsed or refractory multiple myeloma, enrolling 7 patients in the United States. NCT02655822 was a Phase 1/1b study of ciforadenant alone and with atezolizumab in advanced cancers, enrolling 502 patients across the United States, Australia, and Canada.